PALO ALTO — The capital markets have long been challenging for young biotech companies, with revenues still years off and innovations that play out in laboratories and operating rooms—not in the palm of one’s hand.
But as the end of the year looms, the biotech IPO market is booming, reviving the life sciences ecosystem and auguring unprecedented options for companies taking root there.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
